Actionable Items:
Highest Positive Spread: ING Emerging Markets High Dividend Equity Fund (IHD)Focus Stock: Central Securities Corporation (CET)Last Week's Focus Stock: Central Securities CorporationJunk Bonds Debacle: The $85 billion monthly bond-purchase program has produced a selloff for "junk" bonds. The U.S. Treasurys jumped 0.18% to 4.39% on Wednesday. The benchmark 10-Year Treasury note has risen 0.5% in the past month.
About $187 billion of junk bonds have been issued in the U.S. so far this year, a year-to-date record in data going back to 1995. This may be a sell-off of the "junk" bonds. The break in the pattern could mean high yield ("junk") investors may be threatened.
CEF "Junk" Bond Investors: Of the 73 CEFs of "HiYldBndFnds" it is only seven (7) CEFs without leverage. The leverage is 24% of net asset value, which will have to be leveraged again. Of "HiYldBndFnds" the premium is 0.9% and the average monthly yield is 7.2%. For the CEF industry (without HiYldBndFnds), the discount is -3.1% and the distribution yield is 6.0%.
Best Growth Stocks To Watch For 2015: Mitcham Industries Inc.(MIND)
Mitcham Industries, Inc., through its subsidiaries, engages in the leasing, sale, and service of geophysical and other equipment to the seismic industry worldwide. The company operates in two segments, Equipment Leasing and Seamap. The Equipment Leasing segment leases seismic equipment for short-term leasing primarily to seismic data acquisition contractors and oil field service providers. Its land equipment lease pool includes seismic recording land channels, geophones and cables, and other peripheral equipment; marine seismic equipment lease pool comprises streamers, air compressors, air guns, streamer positioning equipment, energy source controllers, and other equipment; and downhole equipment lease pool consist of downhole seismic tools. This segment is also involved in the sale of new seismic equipment of other manufacturers; heli-pickers and related equipment used in the deployment and retrieval of seismic equipment by helicopter; and equipment, consumables, systems integration, engineering hardware, and software maintenance support services to the seismic, hydrographic, oceanographic, environmental, and defense industries, as well as sells used equipment from its lease pool. The Seamap segment designs, manufactures, and sells a range of products for the marine seismic industry. Its products include GunLink seismic source acquisition and control systems, which are designed to provide operators of marine seismic surveys with precise control of energy sources; and BuoyLink RGPS tracking systems that are used to offer precise positioning of seismic sources and streamers. The company was founded in 1987 and is headquartered in Huntsville, Texas.
Advisors' Opinion:- [By Dimitra DeFotis]
The market seems to be showing fatigue particularly with positive onshore oil service data points that may no�longer seem incremental. Investors have become especially focused on potential issues and macro concerns. We believe this phase�of enhanced risk perceptions will pass and still recommend owning selective stocks based on attractive valuations and healthy�fundamentals. Of the 16 oilfield services companies having reported their quarters to date, the share price changes have at times�been difficult to tie to specific results. �… Five of the 12 companies who have beaten earnings expectations have seen their share prices drop on the day, including Basic Energy Services (BAS) (-9.0%), Baker Hughes (BHI) (-2.5%), National Oilwell Varco (NOV) (-1.5%), Oceaneering (OII) (-4.2%), and Schlumberger (SLB) (-2.0%). Other stocks beating expectations have traded higher as expected, including Cameron International (CAM) (+4.1%), FMC Technologies (FTI) (+3.1%), Mitcham Industries (MIND) (+3.8%), Nabors Industries (NBR) (+1.2%), Patterson-UTI Energy (PTEN) (+1.8%), RPC (RES) (+8.4%), and Weatherford International (WFT) (+2.3%). Companies which have missed have universally seen their share prices decline, including Diamond Offshore Drilling (DO) (-4.3%), Gulfmark Offshore (GLF) (-0.1%), and Hercules Offshore (HERO) (-6.9%). Halliburton (HAL) was in line and flat on the day.
5 Best High Dividend Stocks To Own Right Now: Glatfelter (GLT)
P. H. Glatfelter Company manufactures and sells specialty papers and fiber-based engineered materials in the United States and internationally. It offers carbonless and forms papers for credit card receipts, multi-part forms, security papers, and other end-user applications; book publishing papers for the production of hardbound books and other book publishing needs; envelope and converting papers for the direct mail market, shopping bags, and other converting applications; and engineered products for digital imaging, transfer, casting, release, postal, playing card, and other niche specialty applications. The company also provides food and beverage paper used for tea bags and single serve coffee products; metallized products used in the labeling of beer bottles, innerliners, gift wrap, self-adhesive labels, and other consumer products applications; and composite laminates papers used in production of decorative laminates, furniture, and flooring applications, as well as a line of paper products used in batteries, medical masks, and other engineered applications. In addition, it offers airlaid non-woven fabric-like materials used in feminine hygiene products, adult incontinence products, cleaning pads and wipes, food pads, napkins and tablecloths, and baby wipes. The company markets its products directly, as well as through wholesale paper merchants, brokers, and agents. P. H. Glatfelter Company was founded in 1864 and is headquartered in York, Pennsylvania.
Advisors' Opinion:- [By Eric Volkman]
Glatfelter (NYSE: GLT ) has a new asset in its portfolio. The company announced it has finalized the acquisition of Germany-based Dresden Papier, which according to the American firm is "the leading global supplier of nonwoven wallpaper base materials."
- [By CRWE]
Glatfelter (NYSE:GLT) reported that the previously announced presentation by Dante C. Parrini, Chairman and Chief Executive Officer, at the Deutsche Bank Global Industrials and Basic Materials Conference on Wednesday, June 13, 2012 will be available via a live web cast.
5 Best High Dividend Stocks To Own Right Now: Pharmacyclics Inc (PCYC)
Pharmacyclics, Inc., incorporated on April 19, 1991, is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target biochemical pathways involved in human diseases. As of June 30, 2011, it had three drug candidates under clinical development and a number of preclinical lead molecules. This includes an inhibitor of Bruton�� tyrosine kinase (Btk) (PCI-32765) in Phase II studies in hematologic malignancies; a Btk inhibitor lead optimization program targeting autoimmune indications, an inhibitor of Factor VIIa (PCI-27483) in a Phase II clinical trial in pancreatic cancer, and a histone deacetylase (HDAC) inhibitor (PCI-24781) in Phase I and II clinical trials in solid tumors and hematological malignancies as of June 30, 2012.
As of June 30, 2012, the Company developed ibrutinib, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a variety of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse B-cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its current or planned Phase Ib/II and Phase III development program. had development programs for B-cell malignancies and autoimmune diseases. For malignant indications it has developed PCI-32765, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its Phase II development. It has developed an assay! to measure occupancy of Btk in PBMCs using a cell-permeable fluorescently-labeled derivative of PCI-32765.
Factor VII is an enzyme that becomes activated (FVIIa) by binding to the cell surface protein tissue factor (TF), a protein found in the body that helps to trigger the process of blood clotting in response to injury. TF is over expressed in many cancers including gastric, breast, colon, lung, prostate, ovarian and pancreatic cancers. In these tumors, the FVIIa/TF complex induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2), another cell-surface protein. This in turn increases the expression of interleukin-8 (IL-8), a protein produced by white blood cells and other immune cells in response to pathogenic stimulation, and vascular endothelial growth factor (VEGF), a signal protein produced by cells that stimulate the growth of blood vessels. Both proteins play an important role in tumor growth and metastases as well as angiogenesis (growth of new blood vessels). FVIIa/TF complex also initiates the coagulation (a process by which blood forms clots) processes implicated in the high incidence of thromboembolic (the process by which the blood clots within a blood vessel) complications seen in patients with TF-expressing cancers. Thromboembolic events are a cause of death in patients with cancer and anticoagulant treatment has been shown to improve survival in a variety of cancers (Klerk et al. JCO. 2005).
PCI-27483 Factor VIIa Inhibitor
The Company�� Factor VIIa inhibitor PCI-27483 is a first-in-human small molecule inhibitor that selectively targets FVIIa. As an inhibitor of FVIIa, PCI-27483 has two potential mechanisms of action: inhibition of intracellular signaling involved in tumor growth and metastases and inhibition of early coagulation processes associated with thromboembolism.
Factor VIIa PCI-27483 Clinical Development Update
A multicenter Phase I/II of PCI-27483 in patients with locally a! dvanced o! r metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). The objectives are to assess the safety of FVIIa Inhibitor PCI-27483 at pharmacologically active dose levels, to assess potential inhibition of tumor progression and to obtain initial information of the effects on the incidence of thromboembolic events. Due to a paradigm shift away from the use of gemcitabine alone for the treatment of pancreatic cancer, enrolling patients in this randomized study has been challenging. PCYC is evaluating other alternatives for development of this agent.
A multicenter Phase I/II of PCI-27483 in patients with locally advanced or metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). PCI-27483 is covered by United States patents and patent applications and counterpart patents and patent applications in fourteen ex-United States territories, including Europe, Canada, Mexico, Japan, China, India, South Korea, Australia and Brazil.
Advisors' Opinion:- [By Jon C. Ogg]
Pharmacyclics Inc. (NASDAQ: PCYC) was started as Overweight with a $142 price target at J.P. Morgan. Deutsche Bank also started it with a Buy rating and a $170 price target.
5 Best High Dividend Stocks To Own Right Now: Parametric Technology Corporation(PMTC)
Parametric Technology Corporation develops, markets, and supports product lifecycle management (PLM) software solutions and services that help companies design products, manage product information, and enhance product development processes worldwide. Its PLM solutions comprise Windchill, an Internet-based content and process management solution for managing data and relationships, processes, and publications; Arbortext, an enterprise solution to manage complex information assets that enhance their customer support and service center information delivery processes; Creo View, which enables enterprise-wide visualization, verification, annotation, and automated comparison of various product development data formats; and Integrity that coordinates and manages various activities and artifacts associated with developing software-intensive products. The company?s desktop solutions include Creo Parametric, a family of three-dimensional product design solutions based on a parametr ic, feature-based solid modeler that enables changes made during the design process to be associatively updated throughout the design; Creo Elements/Direct, a family of computer aided design and collaboration software used for customers to meet short design cycles and to create product designs; Mathcad, an engineering calculation software solution, which combines a computational engine, accessed through conventional math notation, and with a full-featured word processor and graphing tools; and Arbortext to help customers improve documentation accuracy, speed time to market, reduce translation requirements, and lower publishing costs. In addition, it provides consulting, implementation, training, maintenance, and computer-based training products. Parametric Technology sells its products and services through direct sales force and third-party resellers and other strategic partners. The company was founded in 1985 and is headquartered in Needham, Massachusetts.
Advisors' Opinion:- [By Northrop Puckett]
The company is facing headwinds in the broader economy. This can be seen in declining sales in many areas of their business. Regionally, the U.S was flat; Northern Europe was up; Southern Europe was down; and emerging markets were down. Autodesk also lowered quarterly and yearly revenue expectations. This lowering of guidance by Autodesk also matches the same guidance changes made by competitors Parametric Technology (PMTC) and ANSYS (ANSS), so it is not necessarily losing out to its rivals in this case.
No comments:
Post a Comment